Ipilimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, showed a durable response in metastatic melanoma patients with only four cycles of therapy [5]. The gene discussed is CTLA4; the disease is metastatic melanoma.